FDA has issued the final guidance titled “Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors.” The recommendations for prescription drug and biological products in this guidance are intended to provide a set of principles and recommendations for ensuring that critical elements of a product’s container label and carton labeling are designed to promote safe use of the product. The guidance also provides examples of container label and carton labeling designs that resulted in postmarketing medication errors. This guidance applies to human prescription drug and biological products, including prescription drugs marketed under an approved new drug application or abbreviated new drug application, prescription drugs marketed without an approved application, and biological products marketed under an approved biologics license application. This document finalizes the draft guidance FDA issued in April 2013. The agency made changes from the draft guidance based on comments and information learned through evaluating postmarketing medication errors. These changes include clarifying language that some commenters considered unnecessarily restrictive and emphasizing that labeling statements should be considered within a risk framework. The final guidance has also been updated to reflect regulations and policy that have been established since the draft guidance was published.
Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.
We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.
Interested in gaining an industry edge? Let us help you stay up to date.
Gain an Industry Edge With Expertise From ProPharma Group
Get the latest insights and top tips from our experts, delivered right to your inbox.
Have a complex challenge?